Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Figure 1 | Arthritis Research & Therapy

Figure 1

From: Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis

Figure 1

The level of IL-12 p40 in serum is reduced in STA-5326-treated mice. (a) STA-5326 at a dose of 5 mg/kg or 20 mg/kg or vehicle only was orally administered once a day six days a week from day 0 to day 14 after immunization with human interphotoreceptor retinoid binding protein (IRBP) peptide, and body weight was measured daily. (b) STA-5326 at a dose of 5 mg/kg or 20 mg/kg or vehicle only was orally administered from day 0 to day 14 after immunization. Individual mice sera were collected on day 18 after immunization and the level of IL-12 p40 was assayed by ELISA. Statistical analysis was performed using Student's t-test.

Back to article page